Dow Jones
39 439,16 -73,68 (-0,19 %) Nasdaq
16 374,74 +33,87 (+0,21 %) Nikkei 225
38 179,46 -49,65 (-0,13 %) EUR/USD
1,0794 +0,0022 (+0,21 %) HANG SENG
19 115,06 +151,38 (+0,80 %) Bitcoin EUR
58 095,33 +1 127,13 (+1,98 %)
Sumitomo Pharma Co., Ltd. (DNPUF)
Sumitomo Pharma Co., Ltd.
6-8, Doshomachi 2-chome
Chuo-ku
Osaka 541-0045
Japan
81 6 6203 5321
https://www.sumitomo-pharma.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 6 250
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Hiroshi Nomura | CEO, President & Representative Director | 647,91k | S.O. | 1957 |
| Mr. Toru Kimura Ph.D. | Sr. Mngg Exec. Off. of Glo. Crprate Stgy, F&A, Regen & Cell Med. Off., Kobe Ctr, Mfg. Plt and Dir. | S.O. | S.O. | 1960 |
| Mr. Hiroyuki Baba | Mngg Exec. Officer of Global Data Design, Lgl Affairs. IP, IT Mgt, & Frontier Bus. Off. & Director | S.O. | S.O. | 1959 |
| Mr. Naoki Noguchi | Executive Officer of Corporate Governance & Communications, VP and Head of Corporate Communications | S.O. | S.O. | S.O. |
| Mr. Takuya Taguchi | M.E.O. of Sales & Marketing Div., SVP, Hd of Sales & Marketing Div. and Dep. Hd of Japan Bus. Unit | S.O. | S.O. | S.O. |
| Ms. Atsuko Higuchi | Managing Executive Officer of External Affairs, Corporate Secretariat & Human Resources | S.O. | S.O. | S.O. |
| Mr. Yoshiharu Ikeda Ph.D. | Managing Executive Officer of Drug Research Division, Head of Japan Business Unit & Director | S.O. | S.O. | 1958 |
| Mr. Koichi Kozuki | E.O. of R. Aff., Med. Sci., C.R.C. & Q.A., Sr. VP, Hd of C.R.C. & Q.A. Div and Dp. Hd of Japan Bus. | S.O. | S.O. | S.O. |
| Dr. Shigeyuki Nishinaka Ph.D. | Managing Executive Officer of Business Development & Management and Director | S.O. | S.O. | 1964 |
| Mr. Isao Shimizu | Executive Officer, Senior VP, Head of Drug Research Division & Senior Executive Research Director | S.O. | S.O. | S.O. |
Description
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. It has partnerships with Keio University; RIKEN; Kyoto University; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Sumitomo Pharma Co., Ltd. en date du 1 mai 2024 est 2. Les scores principaux sont Audit : 1; Société : 4; Droits des actionnaires : 3; Compensation : 1.
